




Securities and Exchange Commissions,  
Divisions of Corporate Finance  
450 Fifth Street  
Washington, D.C. 20549  
USA



06013106



26 April 2006

**SEC File Number, 82-34793**

# SUPPL

This information is furnished pursuant to Rule 12g3-2(b).

Please find enclosed information to the Copenhagen Stock Exchange no. 6/2006.

Yours sincerely,  
Coloplast A/S

Leise Rasmussen  
Corp. Communications & IR

Direct tel: +45 4911 1921  
E-mail: dkler@coloplast.com

PROCESSED

MAY 05 2006

THOMSON  
FINANCIAL



*Le 5/4*



**Information to the Copenhagen Stock Exchange no. 6/2006  
Humlebæk, 18 April 2006**

## **Coloplasts divestment of Sterling Medical Services has now been completed**

The divestment of Coloplast's American homecare company Sterling Medical Services LLC (Sterling) to McKesson Corporation was completed 14 April 2006 on the terms described in Coloplast's Information to the Copenhagen Stock Exchange no. 4/2006 of 14 February 2006.

The divestment will result in an immediate, non-recurring capital income of approximately DKK 130m. The parties have agreed not to disclose the purchase price.

The fact that closing was 14 April 2006 and not 1 April 2006 as expected in the stock exchange release of 14 February does not affect Coloplast's expectations for 2005/06. Thus, after the divestment of Sterling and an anticipated closing of the acquisition of Mentor Corporation's urology business 1 June 2006 Coloplast's expectations for 2005/06 remain:

- An organic sales growth of around 10%. The divestment of Sterling affects group sales in 2005/06 negatively by almost DKK 150m in 2005/06. The contemplated acquisition of Mentor's urology business is expected to add approximately DKK 450M sales in the period 1 June 2006 - 30 September 2006.
- An EBIT margin of 12-13%. The operating profit is affected by the contemplated acquisition of Mentor's urology business, including the impact of one-time costs of integrating business systems, depreciation of acquired assets and lower margins on acquired finished goods.

Coloplast's targets for 2012 are also unchanged.

Please refer to Coloplast's Information to Copenhagen Stock Exchange no. 4/2006 for further information about the agreement with McKesson.

Sten Scheibye  
Chief Executive

This announcement is available in a Danish and an English version. In case of doubt the Danish version shall prevail.

For further information: Group director, CFO Lene Skole, phone + 45 4911 1665 or IR manager Jørgen Fischer Ravn, phone + 45 4911 1308